Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
APRESOLINE-ESIDRIX vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Apresoline (hydralazine) is a direct-acting vasodilator that relaxes arteriolar smooth muscle via unknown mechanism; Esidrix (hydrochlorothiazide) is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Hypertension
Hypertension
Hydralazine (Apresoline): Oral, initial 10 mg 4 times daily for first 2-4 days, then increase to 25 mg 4 times daily for first week, then 50 mg 4 times daily thereafter. Maximum daily dose: 300 mg. Hydrochlorothiazide (Esidrix): Oral, initial 12.5-25 mg once daily, may increase to 50 mg once daily if needed.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Hydralazine: 2-8 h (prolonged in renal impairment); Hydrochlorothiazide: 6-15 h (mean 10 h, increased in renal failure).
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Hydralazine undergoes N-acetylation (polymorphic, NAT2) and CYP450; hydrochlorothiazide is not extensively metabolized (excreted unchanged in urine).
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal: Hydralazine 85-90% as metabolites, 5-10% unchanged; Hydrochlorothiazide 95% as unchanged drug. Biliary/fecal: Hydralazine <10%.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Hydralazine: 85-90% (primarily albumin); Hydrochlorothiazide: 40-68% (albumin).
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
Hydralazine: 1.5-1.8 L/kg (extensive tissue distribution); Hydrochlorothiazide: 0.83-1.2 L/kg.
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Hydralazine: 30-50% (oral, extensive first-pass metabolism; slower in slow acetylators); Hydrochlorothiazide: 65-75% (oral).
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
Hydralazine: No adjustment for GFR >10 m L/min; for GFR <10 m L/min, reduce dose to 30-50% of normal. Hydrochlorothiazide: Not effective if GFR <30 m L/min; use alternative diuretic. For Cr Cl 30-50 m L/min, reduce dose or interval.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
Hydralazine: Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated. Hydrochlorothiazide: Caution in severe liver disease due to electrolyte imbalances; no specific dose adjustment defined; use with monitoring.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Hydralazine: Oral, initial 0.75-1 mg/kg/day in 2-4 divided doses, increase over 3-4 weeks to maximum 7.5 mg/kg/day or 200 mg/day. Hydrochlorothiazide: Oral, 1-2 mg/kg/day in 2 divided doses; maximum 6 mg/kg/day or 50 mg/day.
Not established; avoid use in children.
Hydralazine: Start at lower end of dosing range (10 mg 4 times daily) and titrate slowly due to increased sensitivity and risk of hypotension. Hydrochlorothiazide: Start at 12.5 mg once daily, monitor renal function and electrolytes more frequently.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
No black box warning specifically for the combination; hydralazine carries a warning for drug-induced lupus erythematosus.
None
Lupus erythematosus-like syndrome (hydralazine),Hypotension,Myocardial infarction (exacerbation due to reflex tachycardia),Electrolyte imbalances (hypokalemia, hyponatremia) from thiazide,Hyperuricemia,Sulfonamide allergy cross-reactivity (thiazide)
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Hypersensitivity to hydralazine or hydrochlorothiazide,Anuria,Concomitant use with MAO inhibitors,Rheumatic mitral valve disease (hydralazine)
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
Avoid natural licorice (glycyrrhizin) as it can worsen hypokalemia and reduce antihypertensive effect. High-sodium foods should be limited as they can counteract the blood pressure-lowering effect. Grapefruit juice may enhance hydralazine absorption; consistent consumption is advised if intake is routine. Alcohol may potentiate orthostatic hypotension and dizziness.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
APRESOLINE-ESIDRIX (hydralazine/hydrochlorothiazide). First trimester: Hydrochlorothiazide (HCTZ) may cause fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions. Hydralazine has been associated with minor anomalies in animal studies but no well-controlled human studies; risk cannot be ruled out. Second/third trimester: Maternal hypotension may reduce uterine blood flow; HCTZ may cause fetal electrolyte disturbances, thrombocytopenia, and jaundice. Avoid use for edema in pregnancy; use only if clearly needed.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
Hydralazine: M/P ratio unknown; excreted in breast milk in small amounts; unlikely to cause adverse effects in infant. Hydrochlorothiazide: M/P ratio ~0.3; excreted in breast milk; may suppress lactation; use caution, especially if high doses or dehydration.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
Dose adjustments not typically required; however, pregnancy may alter pharmacokinetics (increased volume of distribution, increased renal clearance). Use lowest effective dose; monitor response. Avoid HCTZ for routine edema; use only if other diuretics contraindicated. Start with low doses and titrate slowly.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
APRESOLINE-ESIDRIX is a fixed-dose combination of hydralazine (vasodilator) and hydrochlorothiazide (thiazide diuretic). Monitor for reflex tachycardia and fluid retention with hydralazine; hypokalemia, hyponatremia, and hyperuricemia with hydrochlorothiazide. Use with caution in severe renal impairment (Cr Cl <30 m L/min) and coronary artery disease. May cause lupus-like syndrome with prolonged high-dose hydralazine (usually >200 mg/day). Administer with food to reduce GI upset.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Take this medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,You may experience dizziness or lightheadedness, especially when standing up quickly; rise slowly from sitting or lying down.,Report any unexplained joint pain, rash, fever, or fatigue, as these may be signs of a lupus-like reaction.,Avoid alcohol, which can increase blood pressure-lowering effects and dizziness.,Drink adequate fluids unless otherwise advised by your doctor, but do not increase salt intake without consulting your healthcare provider.,Do not stop taking this medication abruptly, as sudden withdrawal may cause a rapid increase in blood pressure.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about APRESOLINE-ESIDRIX vs ALDORIL 25, answered by our medical review team.
APRESOLINE-ESIDRIX is a Antihypertensive that works by Apresoline (hydralazine) is a direct-acting vasodilator that relaxes arteriolar smooth muscle via unknown mechanism; Esidrix (hydrochlorothiazide) is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between APRESOLINE-ESIDRIX and ALDORIL 25 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of APRESOLINE-ESIDRIX is: Hydralazine (Apresoline): Oral, initial 10 mg 4 times daily for first 2-4 days, then increase to 25 mg 4 times daily for first week, then 50 mg 4 times daily thereafter. Maximum daily dose: 300 mg. Hydrochlorothiazide (Esidrix): Oral, initial 12.5-25 mg once daily, may increase to 50 mg once daily if needed.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between APRESOLINE-ESIDRIX and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. APRESOLINE-ESIDRIX is classified as Category C. APRESOLINE-ESIDRIX (hydralazine/hydrochlorothiazide). First trimester: Hydrochlorothiazide (HCTZ) may cause fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.